Gastrointestinal Cancers Symposium (ASCO GI) | Conference

ctDNA Could Assist in Early Response Assessment in Advanced CRC

January 22nd 2023

Circulating tumor DNA could serve as an ideal biomarker to assess early response in patients with advanced colorectal cancer due to its short half-life compared with other tumor biomarkers, and it could enable the use of adaptive clinical study designs in the future.

Dr. Kopetz on Safety Lead-in Data from the BREAKWATER Trial in BRAF V600E–Mutant mCRC

January 22nd 2023

Scott Kopetz, MD, PhD, FACP, discusses the safety lead-in data from the phase 3 BREAKWATER trial in patients with BRBRAF V600E–mutant metastatic colorectal cancer.

Dr. Wainberg on Liposomal Irinotecan/NALIRIFOX vs Nab-paclitaxel/Gemcitabine in PDAC

January 22nd 2023

Zev A. Wainberg, MD, discusses the evaluation of liposomal irinotecan plus 5-fluorouracil leucovorin, and oxaliplatin vs nab-paclitaxel plus gemcitabine in the phase 3 NAPOLI 3 trial in patients with metastatic pancreatic ductal adenocarcinoma.

Neoadjuvant Chemoradiation Plus Veliparib or Pembrolizumab Fails to Improve NAR Score in Locally Advanced Rectal Cancer

January 21st 2023

Both veliparib plus total neoadjuvant therapy and pembrolizumab plus total neoadjuvant therapy failed to improve short-term outcomes in unselected patients with locally advanced rectal cancer.

Bevacizumab Plus TAS-102 Increases Survival and DCR in mCRC

January 21st 2023

Third-line bevacizumab plus trifluridine/tipiracil demonstrated a survival and disease control benefit vs trifluridine/tipiracil alone in patients with refractory metastatic colorectal cancer and all clinically relevant subgroups.

Newer Therapies Demonstrate Real-world Benefit Vs Sorafenib in First-line HCC

January 21st 2023

Newer frontline therapies demonstrated a real-world improvement in survival and responses compared with sorafenib in patients with hepatocellular carcinoma.

Dr. Tabernero on the Efficacy of Bevacizumab Plus TAS-102 in Refractory mCRC

January 21st 2023

Josep Tabernero, MD, PhD, discusses findings from the phase 3 SUNLIGHT trial investigating the combination of bevacizumab plus trifluridine/tipiracil vs TAS-102 alone in patients with refractory metastatic colorectal cancer.

Dr. Dawson on the Addition of SBRT to Sorafenib in Locally Advanced HCC

January 21st 2023

Laura Dawson, MD, FRCPC, discusses results from the phase 3 NRG/RTOG 1112 trial of stereotactic body radiation therapy plus sorafenib compared with sorafenib alone in patients with locally advanced hepatocellular carcinoma.

CD40-Directed SEA-CD40 Combo Denotes Antitumor Activity in Pancreatic Ductal Adenocarcinoma

January 21st 2023

The combination of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab demonstrated early evidence of efficacy in patients with metastatic pancreatic ductal adenocarcinoma, according to updated results from the phase 1 SGNS40-001 study.

Modest Clinical Benefit Is Observed With or Without Bevacizumab Added to Atezolizumab/Chemotherapy in BTC Signal Seeking Study

January 21st 2023

Treatment with or without bevacizumab added to atezolizumab plus cisplatin/gemcitabine demonstrated a modest clinical benefit for patients with advanced biliary tract cancer.

Tislelizumab Provides QOL Benefit Over Sorafenib in Unresectable HCC

January 21st 2023

Tislelizumab monotherapy resulted in favorable health-related quality of life outcomes compared with sorafenib as frontline treatment for patients with unresectable hepatocellular carcinoma.

Sorafenib Plus SBRT Improves Survival in Locally Advanced HCC

January 21st 2023

The addition of stereotactic body radiation therapy to sorafenib led to an improvement in overall survival, progression-free survival, and time to disease progression compared with sorafenib alone in patients with locally advanced, hepatocellular carcinoma.

Nab-Paclitaxel Plus Gemcitabine/Cisplatin Does Not Significantly Improve OS in Newly Diagnosed, Advanced Biliary Tract Cancers

January 21st 2023

The addition of nab-paclitaxel to gemcitabine and cisplatin did not result in a statistically significant improvement in overall survival over gemcitabine/cisplatin alone in patients with newly diagnosed, advanced biliary tract cancers.

Frontline NALIRIFOX Elicits OS Benefit in Metastatic Pancreatic Ductal Adenocarcinoma

January 21st 2023

First-line treatment with the combination of liposomal irinotecan plus 5-fluorouracil, leucovorin, and oxaliplatin produced a clinically meaningful and statistically significant improvement in overall survival and progression-free survival vs nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma, according to results from the phase 3 NAPOLI 3 trial.

Dr. Shitara on Zolbetuximab Plus mFOLFOX6 in CLDN18.2+, HER2– Gastric/GEJ Adenocarcinoma

January 20th 2023

Kohei Shitara, MD, discusses the evaluation of the combination of zolbetuximab plus mFOLFOX6 in patients with CLDN18.2–positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Dr. Shroff on Results of the SWOG 1815 Trial in Advanced Biliary Tract Cancers

January 20th 2023

Rachna T. Shroff, MD, MS, discusses efficacy data from the phase 3 SWOG 1815 trial investigating nab-paclitaxel plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in newly diagnosed patients with advanced biliary tract cancers.

bTACE Plus Lenvatinib and MWA Produces Responses, Tolerability in HCC

January 20th 2023

Blank-microsphere transarterial chemoembolization plus low-dose lenvatinib and sequential microwave ablation elicited responses and a tolerable safety profile in patients with large hepatocellular carcinoma.

Promising Efficacy and Safety Demonstrated With Envafolimab, Lenvatinib, and TACE in Unresectable HCC

January 20th 2023

Findings from the phase 2 CISLC-12 study show favorable safety and efficacy signals for patients with unresectable hepatocellular carcinoma treated with the combination of envafolimab, lenvatinib, and transarterial chemoembolization.

Anti-drug Antibodies Do Not Affect Durvalumab Alone, With Tremelimumab in Unresectable HCC

January 20th 2023

The presence of anti-drug antibodies appeared to have no effect on efficacy or safety of durvalumab monotherapy or the STRIDE combination of durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma.

LEAP-002 HRQOL Analysis Shows Comparable Scores with Pembrolizumab/Lenvatinib Vs Lenvatinib/Placebo in HCC

January 20th 2023

In the first-line treatment of patients with advanced hepatocellular carcinoma, a combination of pembrolizumab plus lenvatinib yielded similar health-related quality of life scores as lenvatinib plus placebo, according to a HRQOL analysis of the phase 3 LEAP-002 study.